Rx00102 - Etidronate Disodium


Name:
Etidronate Disodium
Rx ID:
Rx00102
Validation Level:
Phenomic Similarity:
0.541
Reference ID:
DB01077
Primary Indications:
Symptomatic Paget's disease of bone; heterotopic ossification; total hip replacement; spinal cord injury
Orphan Indications:
Degenerative metabolic bone disease
Rare Indications:
Hypercalcemia; late-stage cancer
Common Indications:
Paget's disease of bone; heterotopic ossification; total hip replacement; spinal cord injury
Pathways:
superpathway of purine nucleotide salvage
Drug Interactions:
Aluminium; Calcium; Calcium Acetate; Calcium Chloride; Iron; Iron Dextran; Magnesium; Magnesium oxide; Sucralfate; ...
Click to show more...
Food Interactions:
Avoid aluminium, calcium, iron and magnesium within 2 hours of taking medication. Take on an empty stomach with a full glass of water.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00102
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
spinal cord injury heterotopic ossification 7 1497 45 419.275 1.30E-16 4.16e-13
heterotopic ossification spinal cord injury 7 45 1497 419.275 1.30E-16 4.16e-13

Chemical, Pharmacological and Biological Annotations


ATC Code:
M05BA01 M05BB01;
Brands:
Didronel (Procter & Gamble); Etidron (Gentili)
Categories:
Bone Density Conservation Agents; Antihypocalcemic Agents; Bisphosphonates
ChEBI ID:
4907
PubChem ID:
3305
KEGG Drug ID:
D00314
SMILE:
CC(O)(P(O)(O)=O)P(O)(O)=O
InChI:
1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
Classification:
Kingdom:
Organic Compounds
Superclass:
Organophosphorus Compounds
Class:
Organic Phosphonic Acids and Derivatives
Subclass:
Organic Phosphonic Acids
Indication:
For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
Pharmacodynamics:
Etidronic acid is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronic acid affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronic a...
Click to show more...
Description:
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [PubChem]
Mechanism:
Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data sugge...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
-
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
1.9653 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org